Consensus Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.668 ^USD	-0.30%		-14.77%	-26.79%

13/03	Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
12/03	Gossamer Bio Announces Board of Directors Appointments	CI

Evolution of the average Target Price on Gossamer Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1d215f301b7e8.rBgnOaM-3UlJPnj7GMkzMZtDTgA2rpQM_eVvYjVTtYw.-X9XfeJxnwx8ZzuCbZ9LbswVB1p-5vBrhIwaL0Y70tXZKV92y02zcDhxCw~c04caa1cc090ea9d6aa2c370cbe1479d

Analyst Recommendations on Gossamer Bio, Inc.

Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating	06/03	MT
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating	08/01	MT
Wedbush Lifts Gossamer Bio's PT to $6 From $5, Increases Multiple for Seralutinib for Pulmonary Arterial Hypertension in US, EU; Keeps Outperform Rating	10/11	MT
UBS Downgrades Gossamer Bio to Neutral From Buy, Adjusts Price Target to $1.25 From $8	27/23/27	MT
Wedbush Trims Gossamer Bio's Price Target to $5 From $7, Keeps Outperform Rating	26/23/26	MT
Barclays Adjusts Price Target on Gossamer Bio $1.50 From $2, Keeps Equalweight Rating	21/23/21	MT
Raymond James Downgrades Gossamer Bio to Market Perform From Outperform	07/23/07	MT
Guggenheim Initiates Gossamer Bio at Neutral	01/23/01	MT
HC Wainwright Adjusts Gossamer Bio's Price Target to $5 From $25, Keeps Buy Rating	08/22/08	MT
Cantor Fitzgerald Lowers Price Target on Gossamer Bio to $10 From $21, Maintains Overweight Rating	07/22/07	MT
Goldman Sachs Lowers Price Target on Gossamer Bio to $10 From $22, Maintains Buy Rating	07/22/07	MT
UBS Cuts Price Target on Gossamer Bio to $8 From $19, Maintains Buy Rating	07/22/07	MT
JPMorgan Downgrades Gossamer Bio to Underweight From Neutral	07/22/07	MT
SVB Securities Adjusts Gossamer Bio's Price Target to $10 From $15, Keeps Outperform Rating	07/22/07	MT
Raymond James Adjusts Gossamer Bio's Price Target to $5 From $15, Keeps Outperform Rating	07/22/07	MT
Barclays Downgrades Gossamer Bio to Equal Weight From Overweight, Adjusts Price Target to $2 From $18	07/22/07	MT
Wedbush Cuts Gossamer Bio's PT to $7 From $19 After Results From Phase 2 Study of Seralutinib Fell Short of Expectations, Keeps Outperform Rating	07/22/07	MT
SMBC Nikko Downgrades Gossamer Bio to Neutral From Outperform, Price Target is $3	07/22/07	MT
Fed Rate Hike Fears Send US Equity Futures Struggling for Direction	06/22/06	MT
Raymond James Trims Price Target on Gossamer Bio to $15 From $18, Maintains Outperform Rating	17/22/17	MT
Wedbush Adjusts Gossamer Bio's Price Target to $19 From $24 After Increase in Share Count, Keeps Outperform Rating	07/22/07	MT
Goldman Sachs Starts Gossamer Bio at Buy With $22 Price Target	20/22/20	MT
JPMorgan Starts Gossamer Bio at Neutral With $17 Price Target	21/22/21	MT
Wedbush Starts Gossamer Bio at Outperform With $24 Price Target	19/22/19	MT
Barclays Adjusts Gossamer Bio's Price Target to $18 From $12, Reiterates Overweight Rating	17/22/17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.668 USD

Average target price

5.719 USD

Spread / Average Target

+756.10%

High Price Target

15 USD

Spread / Highest target

+2,145.51%

Low Price Target

0.5 USD

Spread / Lowest Target

-25.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gossamer Bio, Inc.

Goldman Sachs
HC Wainwright
Wedbush
UBS
Barclays
Raymond James
Guggenheim
SMBC Nikko
SVB Securities LLC
JPMorgan Chase
Cantor Fitzgerald
Piper Sandler
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar